Richter's Transformation
15
4
5
2
Key Insights
Highlights
Success Rate
22% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
46.7%
7 terminated out of 15 trials
22.2%
-64.3% vs benchmark
0%
0 trials in Phase 3/4
250%
5 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
CD45BE-HSPC + CART-45 Cells
ONO-4538 Study in Patients With Richter's Transformation
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Registry of the German CLL Study Group
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias